Erick DeVinney Net Worth

The estimated Net Worth of Erick Wayne De Vinney is at least $2.41 million dollars as of 16 March 2024. Mr. Vinney owns over 18,675 units of Axogen stock worth over $2,398,567 and over the last 11 years he sold AXGN stock worth over $9,021. In addition, he makes $0 as Vice President - Clinical and Translational Sciences at Axogen.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. DeVinney AXGN stock SEC Form 4 insiders trading

Erick has made over 15 trades of the Axogen stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 18,675 units of AXGN stock worth $248,004 on 16 March 2024.

The largest trade he's ever made was exercising 35,274 units of Axogen stock on 13 November 2018 worth over $95,945. On average, Erick trades about 3,941 units every 75 days since 2014. As of 16 March 2024 he still owns at least 180,615 units of Axogen stock.

You can see the complete history of Mr. Vinney stock trades at the bottom of the page.

Erick DeVinney biography

Erick Wayne DeVinney serves as Vice President - Clinical and Translational Sciences of the Company. Mr. DeVinney has served as Axogen’s Vice President of Clinical and Translational Sciences since January 2014. From April 2007 until January 2014, Mr. DeVinney was the Director of Clinical and Translational Sciences for Axogen. Erick has over 14 years of experience in the successful planning and management of clinical development. Prior to joining Axogen Mr. DeVinney served as Manager of Clinical Operations for Angiotech Pharmaceuticals from 2005 to 2007 and Clinical Program Lead for Pharmaceutical Research Associates International from 2001 to 2005. Mr. DeVinney has been involved in the successful submission of numerous 510(k), IDE and NDA applications. He has a BS in Chemistry from Virginia Commonwealth University.

How old is Erick DeVinney?

Erick DeVinney is 44, he's been the Vice President - Clinical and Translational Sciences of Axogen since 2014. There are 14 older and 1 younger executives at Axogen. The oldest executive at Axogen Inc. is Guido Neels, 71, who is the Independent Director.

What's Erick DeVinney's mailing address?

Erick's mailing address filed with the SEC is 13631 PROGRESS BLVD.,, SUITE 400, ALACHUA, FL, 32615.

Insiders trading at Axogen

Over the last 14 years, insiders at Axogen have traded over $73,805,978 worth of Axogen stock and bought 504,297 units worth $3,119,117 . The most active insiders traders include James E Deerfield Mgmt L.P...., Guido J Neels et Karen L. Zaderej. On average, Axogen executives and independent directors trade stock every 21 days with the average trade being worth of $455,132. The most recent stock trade was executed by John Johnson on 1 September 2024, trading 11,904 units of AXGN stock currently worth $158,085.

What does Axogen do?

it's time to rethink nerve repair! axogen (nasdaq: axgn) is a medical products company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. people suffer traumatic injuries or undergo surgeries that impact the function of their peripheral nerves daily. damage may cause loss of function and feeling. axogen is bringing the science of nerve repair to life with its avance® nerve graft which axogen believes is the first and only commercially available allograft for bridging nerve discontinuities, axoguard® nerve connector, a coaptation aid allowing for close approximation of severed nerves, and axoguard® nerve protector that protects nerves during the healing process.

Complete history of Mr. Vinney stock trades at Axogen

Axogen executives and stock owners

Axogen executives and other stock owners filed with the SEC include:

• Eric Sandberg,
  Chief Commercial Officer
• Karen Zaderej,
  Chairman of the Board, President, Chief Executive Officer
• Gregory Freitag,
  Director
• Angelo Scopelianos,
  Vice President - Research and Development
• Peter Mariani,
  Chief Financial Officer
• Maria Martinez,
  Chief Human Resource Officer
• Quentin Blackford,
  Independent Director
• Alan Levine,
  Independent Director
• Amy Wendell,
  Lead Independent Director
• Mark Gold,
  Independent Director
• Guido Neels,
  Independent Director
• Paul Thomas,
  Director
• Brad Ottinger,
  Chief Compliance Officer, General Counsel
• Isabelle Billet,
  Chief Strategy and Business Development Officer
• Mark Friedman,
  Vice President - Regulatory Affairs and Quality Assurance
• Erick DeVinney,
  Vice President - Clinical and Translational Sciences
• Mike Donovan,
  Vice President - Operations
• James E Deerfield Mgmt L.P....,
  
• John P Engels,
  Vice President
• Jamie Mark Grooms,
  Director
• Robert James Rudelius,
  Director
• Joseph M Mandato,
  Director
• Shawn F Mccarrey,
  SVP of Sales
• Lisa N Colleran,
  Director
• Jon S. Gingrich,
  Chief Commercial Officer
• Woodlands Fund Ix, L.P. Essex,
  10% owner
• Kevin Leach,
  Vice President Marketing
• Kathy Johnson Weiler,
  Director
• William P. Mr. Burke,
  Director
• Lee Robert Jr Johnston,
  Chief Financial Officer
• Jill F Schiaparelli,
  SVP, Bus. Strategy&Marketing
• John Frederick Harper,
  Director
• Bradley Jay Hedger,
  Vice President, Sales
• David K Hansen,
  VP Finance & Treasurer
• Michael Patrick Donovan,
  VP Operations
• Joseph A. Tyndall,
  Director
• John Johnson,
  Director
• Nir Naor,
  CFO
• Marc A Began,
  EVP and General Counsel
• Jens Kemp,
  Chief Marketing Officer
• Michael D Dale,
  CEO and President